Epileptic Seizures Associated with Gliomas in Patients with Newly Diagnosed and Recurrent IDH-Wildtype Glioblastoma: Insights from the 2021 WHO CNS Tumor Classification - Scorecard - MDSpire
Advertisement
Epileptic Seizures Associated with Gliomas in Patients with Newly Diagnosed and Recurrent IDH-Wildtype Glioblastoma: Insights from the 2021 WHO CNS Tumor Classification
Clinical Scorecard: Epileptic Seizures Associated with Gliomas in Patients with Newly Diagnosed and Recurrent IDH-Wildtype Glioblastoma: Insights from the 2021 WHO CNS Tumor Classification
At a Glance
Category
Detail
Condition
Glioma-related epilepsy (GRE) in IDH-wildtype glioblastoma (GBM)
Key Mechanisms
Epileptogenicity linked to tumor pathology, IDH mutation status, and tumor grade; IDH-wildtype GBM defined by microvascular proliferation, necrosis, TERT promoter mutation, EGFR amplification, or chromosome 7 gain/chromosome 10 loss
Target Population
Adult patients (≥18 years) with newly diagnosed or recurrent IDH-wildtype GBM
Care Setting
Neurosurgical and neuro-oncology clinical settings with surgical intervention and postoperative management
Key Highlights
GRE incidence in adult diffuse gliomas ranges from 40% to 90%, influenced by tumor pathology and grade.
IDH-wildtype GBM classification updated in 2021 WHO CNS tumor classification, impacting GRE understanding.
Postoperative seizure control assessed by occurrence of unprovoked seizures within one year after surgery.
Guideline-Based Recommendations
Diagnosis
Confirm GBM, IDH-wildtype diagnosis per 2021 WHO criteria including molecular markers (IDH-wildtype, TERT promoter mutation, EGFR amplification, chromosome 7 gain/10 loss).
Assess preoperative GRE by patient history of unprovoked seizures prior to surgery.
Evaluate extent of resection (EOR) via MRI within 72 hours post-surgery to categorize as gross total resection (GTR) or non-GTR.
Management
Initiate or adjust valproate or levetiracetam promptly for patients presenting with GRE preoperatively.
Administer prophylactic anti-seizure medications postoperatively: phenobarbital injections within three days, followed by valproate or levetiracetam for at least three months.
Apply standard adjuvant therapy (Stupp protocol) including radiation and temozolomide as indicated.
Monitoring & Follow-up
Longitudinally monitor seizure outcomes through scheduled visits or telephone interviews for at least one year post-surgery.
Classify seizure control as inadequate if any unprovoked seizures occur within one year after surgery.
Risks
GRE is often difficult to control even with appropriate anti-tumor treatment.
GRE significantly impacts patient quality of life, independence, and mental health.
Incomplete tumor resection may influence postoperative seizure control.
Patient & Prescribing Data
Adult patients with newly diagnosed or recurrent IDH-wildtype GBM undergoing surgical treatment
Valproate and levetiracetam are primary anti-seizure medications used pre- and postoperatively; phenobarbital used immediately post-surgery; seizure control requires ongoing monitoring for at least one year.
Clinical Best Practices
Use integrated molecular and histopathological criteria per 2021 WHO classification for accurate GBM diagnosis.
Implement early and sustained anti-seizure medication protocols for patients with GRE.
Ensure thorough postoperative imaging to assess extent of resection and guide prognosis.
Conduct regular follow-up to detect seizure recurrence and adjust management accordingly.
Consider psychological support to address anxiety and depression related to GRE.
